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The human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several
kinase inhibitors and therapeutic antibodies. While the endosomal trafficking of many other
receptor tyrosine kinases is known to regulate their oncogenic signalling, the prevailing view
on HER2 is that this receptor is predominantly retained on the cell surface. Here, we find that
sortilin-related receptor 1 (SORLA; SORL1) co-precipitates with HER2 in cancer cells and
regulates HER2 subcellular distribution by promoting recycling of the endosomal receptor
back to the plasma membrane. SORLA protein levels in cancer cell lines and bladder cancers
correlates with HER2 levels. Depletion of SORLA triggers HER2 targeting to late endosomal/
lysosomal compartments and impairs HER2-driven signalling and in vivo tumour growth.
SORLA silencing also disrupts normal lysosome function and sensitizes anti-HER2 therapy
sensitive and resistant cancer cells to lysosome-targeting cationic amphiphilic drugs. These
findings reveal potentially important SORLA-dependent endosomal trafficking-linked vul-
nerabilities in HER2-driven cancers.
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The human epidermal growth factor receptor 2 (HER2; alsoknown as ErbB2) is a receptor tyrosine kinase and a well-established oncogene. HER2 amplification is found in
15–20% of breast cancers1,2, and HER2 overexpression or acti-
vating mutations are clinically relevant in other solid tumours
such as bladder cancer, gastric, colorectal, and lung adenocarci-
noma3–5. The biological relevance of HER2 as a driver oncogene
is undisputed, and several targeted therapies have been approved
for treating HER2-dependent cancers.
Several previous studies, including ours, demonstrate that the
oncogenic signalling and the endosomal traffic of many receptor
tyrosine kinases are functionally coupled6–9. Endosomal traf-
ficking critically controls, for instance, the strength and duration
of signals emanating from the epidermal growth factor receptor
(EGFR; also known as ErbB1) and MET6,10,11. However, in
comparison to other receptor tyrosine kinases, the details of
HER2 trafficking are poorly understood. The prevailing view,
supported by two different models, is that HER2 resides almost
exclusively on the plasma membrane in HER2-amplified cancer
cell lines12. Data in favour of a ‘limited internalization’ model
suggest that HER2 resists internalization due to (1) the absence of
identified ligands required for induction of endocytosis13, (2) the
absence of a recognizable internalization motif14, (3) inhibition of
clathrin-coated pit formation15,16, (4) association with membrane
protrusions17 and (5) heat shock protein 90 (HSP90)-dependent
stabilization of HER2 on the plasma membrane18–20. On the
other hand, data in support of a model for ‘rapid recycling’
resulting in nearly exclusive cell-surface localization of HER2
have been brought forward21–23. Hence, key outstanding
questions are: does HER2 undergo endosomal trafficking in
HER2-driven cancer cells, and what would be the functional
consequence of HER2 trafficking for its oncogenic properties?
SORLA is a multifunctional intracellular sorting protein
belonging to the sortilin and LDL-receptor families consisting of a
large extracellular domain, a transmembrane domain and a short
cytoplasmic tail24, which is essential for its membrane sorting
functions25,26. SORLA has been implicated in regulating amyloid
precursor protein (APP) processing during the pathogenesis of
Alzheimer’s disease (AD)27–29 and in lipid metabolism and
obesity30–33. We made the unexpected observation that SORLA is
highly expressed specifically in HER2-driven cancers where
SORLA levels correlate with HER2 subcellular localization. We
find that SORLA co-precipitates with HER2 and regulates its
trafficking from intracellular compartments to the plasma
membrane. However, at this point, we do not know whether
SORLA interacts directly with HER2 or if they are coupled
through a molecular complex or an intermediary partner.
Regardless, we show that SORLA is necessary for oncogenic
HER2 signalling in vitro and in vivo. Depletion of SORLA
induces lysosome dysfunction and results in mislocalization of
signalling-defective HER2 protein to lysosomes. As a result,
SORLA depletion halts tumorigenesis and sensitizes cancer cells
to a clinically relevant lysosome-targeting drug. Taken together,
our data demonstrate that SORLA has previously unrecognized
oncogenic functions in carcinomas.
Results
SORLA co-localizes with HER2 on the plasma membrane and
in intracellular vesicles. Analysis of different breast cancer cell
lines revealed prevalent SORLA protein expression in cells with
HER2-amplification (Fig. 1a). In addition, SORLA was highly
expressed in the 5637 bladder cancer cell line harbouring a
HER2-activating mutation (S310F)34 when compared to the
HER2-low T24 cell line and a primary patient-derived bladder
cancer cell line (Supplementary Fig. 1a). As SORLA has not
previously been scrutinized in carcinoma cells, we first examined
cellular SORLA levels in a quantitative manner. Flow cytometry
(FACS) analysis revealed BT474 cells to have the highest cell-
surface levels of SORLA compared to MDA-MB-361 cells
(intermediate expression) and JIMT-1 cells (lowest expression)
(Fig. 1b), further validating the correlation between total SORLA
and HER2 levels observed by western blotting (Fig. 1b; Supple-
mentary Fig. 1b). Next, we investigated the subcellular localiza-
tion of SORLA in different endosomal compartments.
Endogenous SORLA was found to localize largely to early
endosomes (identified by EEA1 and Rab5 expression) and ret-
rograde vesicles (VPS35) in MDA-MB-361 breast cancer cells
(Supplementary Fig. 1c). The SORLA-GFP fusion protein was
similarly detected in EEA1- and VPS35-positive vesicles, and
while present in recycling endosomes (Rab11) (Supplementary
Fig. 1c), was not detected in late endosomes (Rab7) or lysosomes
(LAMP1) (Supplementary Fig. 1c).
Previous studies have indicated that HER2 is mainly restricted
to the plasma membrane12; however, these observations were
based on a very limited number of cell lines and/or on exogenous
HER2 overexpression13,17,21. Since SORLA, an important sorting
protein in neuronal cells and adipocytes, is expressed in HER2-
positive cancer cells (Fig. 1a), we were interested to re-examine
the subcellular localization of endogenous HER2 in breast cancer
cells with variable levels of SORLA expression (Fig. 1a, c;
Supplementary Fig. 1d). In the BT474 and SKBR3 cells with high
SORLA expression, HER2 was mainly on the plasma membrane,
in accordance with previous work17,21, and did not overlap with
EEA1-positive endosomes (Fig. 1a, c, Supplementary Fig. 1d). A
similar distribution was apparent in the third SORLA-high cell
line HCC1419 (Fig. 1a, Supplementary Fig. 1d). However, in cells
with intermediate (MDA-MB-361) or low (HCC1954 and
JIMT-1) SORLA expression, HER2 was also distributed intra-
cellularly indicating that HER2 must be trafficked at least in a
subset of HER2 cancers (Fig. 1c, Supplementary Fig. 1d). The
distinct cell-surface HER2 levels were further validated with
FACS (Supplementary Fig. 1e). With respect to the intracellular
HER2 pool, a proportion of the receptor demonstrated a clear
overlap with EEA1, indicating localization in early endosomes
(Fig. 1c, d). In MDA-MB-361 cells, endogenous SORLA co-
localized with HER2 in EEA1-positive early endosomes (Fig. 1d),
and in the SORLA-low JIMT-1 cells, SORLA-GFP localized to
HER2 and VPS35-positive intracellular vesicles (Fig. 1d). When
SORLA-GFP expression was analysed in JIMT-1 cells (n= 130),
19.8 ± 0.8 percent of SORLA-GFP overlapped with intracellular
HER2 (Supplementary Fig. 1f) showing Pearson’s R of 0.3 ± 0.01
indicative of partial co-localisation.
To study whether SORLA and HER2 would show similar
dynamics in cells, we chose to image the MDA-MB-361 cells
expressing intracellular as well as cell-surface pools of HER2. For
visualization, we performed live-cell TIRF imaging (allowing
visualization of events close to the plasma membrane) of SORLA-
GFP and HER2 labelled with Alexa568-conjugated anti-HER2
antibody (trastuzumab; Tz-568). Short-lived SORLA- and HER2-
positive structures were detected in the TIRF-plane, indicative of
active dynamics to and from the plasma membrane. In addition,
co-localizing puncta of SORLA and HER2 were frequently
observed undergoing dynamic lateral movement on the plasma
membrane (Supplementary Fig. 1g and Supplementary Movie 1).
Live-cell imaging deeper in the cytoplasm showed that SORLA
and HER2 move together within the same endosomal structures
(Supplementary Fig. 1g and Supplementary Movie 2). Collec-
tively, these data demonstrate that SORLA and HER2 undergo
co-trafficking between the plasma membrane and endosomes.
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The SORLA extracellular domain is required for
SORLA–HER2 complex formation. Intrigued by the apparent
co-trafficking of SORLA and HER2, we next performed a set of
co-immunoprecipitation assays to investigate whether HER2 and
SORLA associate. We found that endogenous HER2 and SORLA
co-precipitate in MDA-MB-361 and BT474 cells, indicating that
HER2 and SORLA may exist in the same protein complex
(Fig. 1e). SORLA consists of an extracellular domain (ECD), a
transmembrane domain (TM) and a short cytosolic domain (CD)
(Fig. 1f). To dissect the SORLA─HER2 association further, we
generated truncated SORLA-GFP fusions consisting of either the
SORLA extracellular and transmembrane domains (ECD+ TM)
or the SORLA transmembrane and cytosolic domains (TM+
CD) (Fig. 1f, g). HER2 co-precipitated with the full-length
SORLA-GFP and with SORLA-GFP ECD+ TM in cells, but
failed to associate with SORLA-GFP TM+ CD (Fig. 1g). Inter-
estingly, SORLA-GFP TM+ CD showed similar vesicular loca-
lization as full-length SORLA-GFP, whereas SORLA-GFP ECD
+ TM was found diffusely in membrane-compartments in the
cytoplasm and on the plasma membrane (Supplementary Fig. 2a).
Thus, while the SORLA ECD is necessary for the SORLA-HER2
protein complex, the SORLA CD appears to be required for
correct subcellular localization of SORLA.
The SORLA ECD is subdivided into five domains: an N-
terminal VPS10p domain followed by a β-propeller (BP), an EGF-
like (EGF) domain, a complement type repeat-cluster (CR-C) and
a FNIII-domain cluster (Supplementary Fig. 2b). To investigate
which domain of SORLA is required for the SORLA─HER2
complex formation, we produced and purified myc and 6xHIS-




























































































































































































































Fig. 1 SORLA is highly expressed in HER2-amplified breast cancer cells and co-traffics with HER2. a Western blot analysis of SORLA and HER2 protein
levels in breast cancer cell lines. α-tubulin is a loading control. b Quantification of SORLA cell-surface levels by FACS in MDA-MB-361, BT474 and JIMT-1
cells (n= 3 independent experiments; data are geo mean fluorescence intensity (MFI) ± standard error of mean (s.e.m.). c Confocal microscopy imaging of
HER2 (magenta) and EEA-1 (green) in BT474, MDA-MB-361 and JIMT-1 cells. Co-localisation of the HER2 and EEA1 signals is indicated in white in the
merged panels. d Endogenous SORLA (green), HER2 (magenta) and EEA-1 (white) staining in MDA-MB-361 cells (top panel). Endogenous HER2
(magenta) and VPS35 (white) staining in JIMT-1 cells expressing SORLA-GFP (green) (bottom panel). e Co-immunoprecipitation of endogenous SORLA
with endogenous HER2 in MDA-MB-361 and BT474 cells. f Schematic of the SORLA protein domains and summary of the constructs used. g Co-
immunoprecipitation of endogenous HER2 with different SORLA-GFP fragments in MDA-MB-361 cells. Scale bars: 10 µm. Where immunoblots and
micrographs are shown, these are representative of n= 3 independent experiments; IB immunoblotting, IP immunoprecipitation. ECD extracellular domain,
TM transmembrane domain, CD cytosolic domain
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(CR-C, BP-EGF and BP-EGF+ CR-C). Pull-down assays with the
recombinant fragments showed that the full-length SORLA ECD
forms a complex with endogenous HER2 (BT474 cell lysate)
(Supplementary Fig. 2c). In fact, all ECD fragments tested pulled
down HER2 (Supplementary Fig. 2c), suggesting that several,
potentially weak affinity, direct or indirect extracellular interac-
tions regulate the SORLA─HER2 complex formation.
SORLA regulates HER2 cell-surface levels and HER2 oncogenic
signalling. The apparent inverse correlation between SORLA
levels and the proportion of intracellular HER2 in the different
HER2 cell lines (Fig. 1a, c, Supplementary Fig. 1d) prompted us to
hypothesize that cell-surface HER2 levels may be regulated by
SORLA. To test this, we performed loss-of-function experiments
in high-SORLA BT474 cells and gain-of-function experiments in
intermediate/low SORLA cell lines MDA-MB-361 and JIMT-1
cells, respectively. In BT474 cells, with predominantly
plasma membrane-localized HER2 and high SORLA expression,
silencing of SORLA resulted in, approximately, a 50% decrease in
cell-surface HER2 protein levels (Fig. 2a). Conversely, in the
SORLA-intermediate MDA-MB-361 and SORLA-low JIMT-
1 cells, in which HER2 localizes more to endosomal structures,
SORLA overexpression increased cell-surface HER2 levels sig-
nificantly (Fig. 2a). Total HER2 protein levels followed a similar
trend of being significantly downregulated in SORLA-silenced
BT474 cells and upregulated in SORLA-overexpressing MDA-
MB-361 and JIMT-1 cells (Fig. 2b, c). Although the reduction in
total HER2 protein levels upon SORLA silencing was observed
consistently, its extent varied among experiments. Quantitative
PCR analysis of ERBB2 mRNA levels after SORLA silencing or
overexpression did not show any significant differences indicating
that SORLA-mediated regulation of HER2 occurs predominantly
at the post-transcriptional level (Supplementary Fig. 3a). These
effects of SORLA silencing may not be limited to regulation of
HER2 alone; we find that cell-surface β1-integrin levels were also
reduced upon SORLA silencing (Supplementary Fig. 3b).
HER2 amplification is a major driver of proliferation and
tumorigenesis, which prompted us to explore whether SORLA
plays a functional role in breast cancer cells. Efficient silencing of
SORLA in HER2-amplified, SORLA-high BT474 cells signifi-
cantly reduced cell proliferation (Fig. 2d, Supplementary Fig. 3c
−d). This was specifically due to loss of SORLA rather than off-
target effects, given that silencing SORLA with five individual
siRNAs significantly reduced BT474 cell proliferation (Supple-
mentary Fig. 3d, e). Conversely, in the SORLA-low JIMT-1 cells,
expression of SORLA-GFP, triggering HER2 upregulation on the
plasma membrane (Fig. 2a), significantly increased proliferation
of these cells (Fig. 2e, Supplementary Fig. 3f). When SORLA was
silenced in non-HER2-amplified but FGFR2-amplified MFM-223
breast cancer cells (Fig. 1a), there was no effect on cell
proliferation (Supplementary Fig. 3g), indicating that SORLA is
required for proliferation only in HER2-dependent cancer cells.
HER2 signalling on the plasma membrane along the PI3K/
AKT pathway is critical for HER2 growth-promoting functions in
cancer cells. Silencing of SORLA in BT474 and MDA-MB-361
cells led to decreased phosphorylation of AKT (Ser473) and 4E-
BP1 (Thr37/46) as well as decreased cyclin D1 levels, but did not
inhibit mitogen-activated protein kinase (ERK1/2) signalling
(Fig. 2f, Supplementary Fig. 3h). Taken together these data
suggest that SORLA silencing specifically attenuates cell prolif-
eration and PI3K-dependent HER2 signalling in HER2-
amplified cells.
To investigate further the requirement of SORLA expression
for the proliferation of HER2-dependent cancer cells, we silenced
SORLA in the intermediate SORLA expressers, MDA-MB-361
cells, with a 3′UTR targeting siRNA and then re-expressed
SORLA in the same cells. Re-expression of SORLA-GFP in
SORLA-silenced MDA-MB-361 cells fully rescued cell prolifera-
tion back to control levels (Fig. 2g, Supplementary Fig. 3i).
Importantly, only full-length SORLA-GFP, and not the SORLA
fragments lacking either HER2 binding function (SORLA-GFP
TM+CD) or correct subcellular localization (ECD+ TM), was
sufficient to rescue the effect of SORLA silencing on MDA-MB-
361 cell proliferation (Fig. 2h). This suggests that the direct or
indirect interaction of SORLA with HER2 and SORLA sorting
functions are both necessary for SORLA-mediated proliferation
of HER2-dependent cancer cells.
Importantly, silencing SORLA compromised the in vivo
tumour engraftment of HER2-amplified breast cancer cells in
an orthotopic model. SORLA-silenced and control MDA-MB-361
cells were generated by transducing two short hairpin RNAs
(shRNAs) targeting SORLA (shSORLA #1 and shSORLA #4) and
a non-targeting control (shCTRL). Efficient SORLA silencing
strongly inhibited in vitro proliferation of these cells (Supple-
mentary Fig. 3j, k). When control-silenced cells were injected into
the mammary ducts of immunocompromised NOD.SCID mice,
multiple ductal carcinoma in situ (DCIS) lesions were formed
within 10 weeks. In contrast, the development of DCIS tumours
from SORLA-silenced xenografts was almost completely halted
(Fig. 2i). Taken together these data indicate that SORLA
functionally regulates both the expression and the oncogenic
function of HER2 in breast cancer.
SORLA promotes HER2 recycling. The steady-state distribution
of cell-surface receptors between endosomes and the plasma
membrane is regulated by the respective rates of receptor inter-
nalization and recycling back to the plasma membrane. To study
whether SORLA regulates this balance in HER2 cell lines, we
investigated HER2 localization and trafficking in the presence and
absence of SORLA. First, we silenced SORLA in BT474 cells with
high SORLA levels and predominantly plasma membrane HER2
localization at steady state. Interestingly, shRNA-mediated
SORLA silencing led to increased intracellular accumulation of
HER2, normally not observed in these cells (Fig. 3a, b). A similar
shift in HER2 subcellular localization was triggered when inhi-
biting vesicular recycling with primaquine, indicating that HER2
undergoes constant endocytosis balanced with very rapid recy-
cling in cells with predominantly plasma membrane-localized
HER2 and that SORLA may play a role in facilitating HER2
transport (Fig. 3c, d).
Next, we investigated HER2 dynamics in MDA-MB-361 cells,
where HER2 is localized both endosomally and on the plasma
membrane, and in which SORLA is expressed at intermediate
levels. SORLA-silenced MDA-MB-361 cells were subjected to an
imaging-based receptor uptake assay. Cell-surface HER2 was
labelled with AlexaFluor 568-conjugated trastuzumab (Tz-568)
on ice and receptor internalization was then induced by placing
cells at +37oC for 15, 30, and 60 min before fixation. SORLA-
silenced cells showed significantly greater accumulation of
intracellular HER2 after 30 min of internalization when com-
pared to control-silenced cells (Fig. 3e, f), suggesting a possible
defect in recycling. To test this, we labelled cell-surface HER2 as
above, allowed receptor trafficking for 45 min, removed the
remaining cell-surface-bound Tz-568 antibody with an acid wash
and then allowed receptor recycling to occur for 30 min. SORLA-
silenced MDA-MB-361 cells demonstrated significantly greater
retention of intracellular antibody, indicative of attenuated
recycling (Fig. 3g). To investigate the role of SORLA in receptor
traffic further, we utilized JIMT-1 cells, which express very low
endogenous SORLA, contain a substantial fraction of intracellular
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HER2 at steady state and where the overexpression of SORLA
leads to increased HER2 cell-surface levels (Fig. 2a). Over-
expression of SORLA-GFP in these cells prevented the intracel-
lular accumulation of cell-surface biotinylated HER2 when
compared to control transfected cells (Fig. 3h), suggesting
possibly accelerated recycling. Furthermore, a biochemical
recycling assay, in which biotin is cleaved off from an internalized
biotinylated receptor upon recycling back to the plasma
membrane, revealed that SORLA-GFP-expressing JIMT-1 cells
recycle significantly more HER2 to the plasma membrane
compared to JIMT-1 control cells (Fig. 3i). A more detailed time
course (5, 10 and 15 min of recycling) indicated that HER2
recycling is higher in SORLA-GFP cells, compared to GFP cells,
only at 10 min, possibly due to rapid re-endocytosis of the
recycled HER2 in the SORLA-GFP cells (Supplementary Fig. 4a).
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β1-integrins (without influencing endocytosis; Supplementary
Fig. 4b, c), suggesting that in cancer cells SORLA could be linked
to trafficking of other receptors in addition to HER2. Taken
together, these findings demonstrate a role for SORLA in the
regulation of HER2 recycling.
Silencing SORLA triggers HER2 accumulation in dysfunc-
tional lysosomes. As SORLA silencing triggered increased
intracellular retention of HER2 in the internalization assays, we
wanted to investigate the subcellular localization of HER2 in
SORLA-silenced MDA-MB-361 cells. Imaging revealed striking
accumulation of HER2 in enlarged LAMP-1-positive structures
(late endosomes/lysosomes), not observed in control cells (Fig. 4a,
Supplementary Fig. 5a). The accumulation of HER2 in these
structures, within SORLA-silenced cells, is rather surprising as
under normal conditions, lysosomal targeting of growth factor
receptors is linked to rapid receptor degradation. However, HER2
protein levels in SORLA-silenced cells were only modestly
reduced (Supplementary Fig. 5a), suggesting that attenuated
HER2 signalling (Fig. 2f, Supplementary Fig. 3i) is not linked to
receptor degradation. Instead, since the ligand for PI3K, PI(4,5)
P2, is predominantly enriched on the plasma membrane and
considered to be absent from late endosomes, this may explain
the restricted HER2 signalling, through the PI3K/AKT pathway,
from these compartments in SORLA-silenced cells.
Given the enlarged LAMP-1 structures and the apparent
discrepancy between increased lysosomal localization of HER2
versus minimal effects on HER2 levels, we investigated whether
loss of SORLA could be potentially linked to abnormal lysosome
function. Our hypothesis was supported by strong perinuclear
accumulation of LAMP1- and CD63 (LAMP3)-positive late
endosomes/lysosomes in SORLA-silenced cells compared to
control cells (Fig. 4b, c, Supplementary Fig 5b, c). Lysosomal
aggregation was confirmed with four different siRNAs targeting
SORLA in both MDA-MB-361 and BT474 cells (Supplementary
Fig. 5d). Thus, depletion of endogenous SORLA in breast cancer
cells leads to altered subcellular localization of lysosomes.
Interestingly, this is linked to the altered traffic of HER2, as dual
silencing of HER2 and SORLA reduced lysosomal aggregation but
did not fully revert the phenotype (Fig. 4d). This suggests that in
SORLA-silenced cells, HER2 localization to lysosomes contributes
to compromised lysosomal function. This is further supported by
the fact that SORLA silencing in the non-HER2-amplified breast
cancer cell line MFM-223 does not affect the subcellular
localization of lysosomes (Supplementary Fig. 5e).
Further analyses using transmission electron microscopy
(TEM) revealed enlarged lysosomes in SORLA-silenced cells
suggesting potential lysosome maturation defects (Fig. 4e). To
monitor the proteolytic activity of lysosomes, we analysed loss of
quenching of a fluorogenic protease substrate, DQ Red BSA,
loaded into cells35. SORLA-silenced MDA-MB-361 cells showed
significantly lower DQ Red BSA signal (indicating reduced
lysosomal cleavage of BSA), detected either by confocal micro-
scopy imaging (Supplementary Fig. 5f) or by flow cytometry, than
the respective control cells (Fig. 4f). These data together indicate a
link between SORLA-dependent HER2 signalling and lysosome
integrity in HER2-driven cancer cells.
Depletion of SORLA renders HER2-driven cancer cells sensi-
tive to CADs. Previous studies indicate that cancer cells possess
functionally abnormal lysosomes making them more susceptible
to cationic amphiphilic drugs (CADs), a heterogeneous class of
molecules with a similar chemical structure resulting in lysosomal
accumulation and increased lysosomal membrane permeabiliza-
tion36. Recently, cancer cells were shown to be more sensitive to
CAD-induced cell death than non-transformed cells37. Given the
defective lysosomes of SORLA-depleted cells, we wanted to
evaluate the response of anti-HER2 therapy-sensitive BT474 and
therapy-resistant MDA-MB-361 cells to the antihistamine ebas-
tine, a CAD with cytotoxic effects in lung cancer37. Interestingly,
ebastine displayed significantly lower IC50 values when tested for
growth inhibitory effects in both of these HER2-amplified breast
cancer cells following SORLA silencing (Fig. 4g). Moreover,
treatment of SORLA-silenced MDA-MB-361 cells with 15 µM
ebastine, which is close to the determined IC50 value that inhibits
the growth of these cells, significantly increased the levels of
cleaved PARP1, indicative of apoptosis, whereas no such effect
was seen in control-silenced cells (Fig. 4h, i). Thus, depletion of
SORLA increases the sensitivity of breast cancer cells to CADs,
regardless of susceptibility to anti-HER2 therapy, presumably due
to apoptosis triggered by lysosomal dysfunction. These data
indicate that compromised lysosomal integrity downstream of
SORLA depletion could be exploited therapeutically to induce cell
death in anti-HER2 therapy-resistant breast cancer cells.
High SORLA expression correlates with poor patient outcome
specifically in HER2-amplified breast cancer patients. Our
in vitro data and observations of reduced tumour formation in
mice demonstrate an important role for SORLA in regulating
HER2 function in breast cancer cells. Next, we evaluated HER2
levels and SORLA expression in clinical specimens of breast
cancer. Immunohistochemical staining of SORLA in a breast
cancer tissue microarray (TMA) revealed that a substantial
Fig. 2 SORLA regulates HER2 cell-surface levels and oncogenic signalling in breast cancer cells. a−c SORLA-high BT474 cells were subjected to shRNA-
mediated control (shCTRL) or SORLA (shSORLA #1 and #4) silencing. SORLA-intermediate/low MDA-MB-361/JIMT-1 cells were transfected with
SORLA-GFP or GFP alone. Flow cytometry analysis of cell-surface HER2 levels (a, MFI ± standard deviation (s.d.); n= 3 independent experiments),
immunoblotting of total HER2 and SORLA, where α-tubulin is a loading control (b) and quantification of total HER2 protein levels relative to loading
control (c) are shown (mean ± s.d.; n= 3 independent experiments; statistical analysis: unpaired Student’s t test). d Proliferation of BT474 cells after
SORLA silencing with siRNAs (mean ± s.d. of n= 12, four technical replicates, three independent experiments; statistical analysis: two-way ANOVA).
e Proliferation of parental, GFP control and SORLA-GFP overexpressing JIMT-1 cells (mean ± s.d. of n= 12, four technical replicates, three independent
experiments; statistical analysis: two-way ANOVA). f Western blot analysis of the indicated signalling proteins (phosphorylated and total) in BT474 cells
after scramble (siCTRL) and SORLA silencing (siSORLA #3 and siSORLA #4). α-tubulin is a loading control. m.#1 indicates membrane number 1 and m.#2
indicates membrane number 2 (n= 2 independent experiments). g Proliferation of MDA-MB-361 cells expressing SORLA-GFP or GFP-control after
silencing with control siRNA (siCTRL) or siRNA against the 3′UTR of SORLA (siSORLA 3′UTR) (mean ± s.d. of n= 14 from four independent experiments,
two-way ANOVA). h Proliferation of MDA-MB-361 cells expressing SORLA-GFP constructs (full-length, ECD-TM or TM-CD) after silencing with siCTRL or
siSORLA 3′UTR (mean ± s.d. of n= 8 from two independent experiments; statistical analysis: two-way ANOVA). i Quantification of mammary DCIS
tumours (Carnoy staining) 10 weeks after injection of shSORLA- and shCTRL-silenced MDA-MB-361 cells into the mammary ducts of NOD.SCID mice
(box plot represents median and 25th and 75th percentiles—interquartile range; IQR—and whiskers extend to maximum and minimum values; n= 9 mice
per group; statistical analysis: unpaired Student’s t test). Scale bars: 2 mm
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proportion (38%) of HER2-amplified breast cancers express
moderate to high SORLA, indicating that HER2-amplified breast
cancers fall into two subtypes with respect to SORLA positivity
(Fig. 5a). However, in spite of a lack of overall correlation
between HER2 amplification and SORLA expression in breast
cancer, high SORL1 expression appears to predict poor relapse-
free and overall survival specifically within HER2-amplified breast
cancer patients (Fig. 5b) according to the in silico biomarker
assessment tool38 (http://kmplot.com), which interrogates large
datasets (e.g. The Cancer Genome Atlas (TCGA), the European
Genome Phenotype Archive (EGA) and the Gene Expression
Omnibus (GEO)) in its analysis. Thus, SORLA levels could have a
prognostic value in HER2-amplified breast cancers.
SORLA correlates with HER2 and regulates proliferation and
tumour growth in bladder cancer. To broaden our study for
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clinically relevant39,40, we stained SORLA in a bladder cancer
TMA of 199 patients. In this cancer type HER2 and SORLA levels
correlated significantly (chi-square test, p= 0.0092), whereas
there was no correlation between SORLA and EGFR levels
(Fig. 6a, Supplementary Fig. 6a). This led us to test if SORLA also
plays a role in the regulation of HER2 cell-surface levels, cell
proliferation and cell sensitivity to CADs or in vivo tumour
growth in this cancer model. Silencing of SORLA in 5637 cells, a
bladder carcinoma cell line with a HER2-activating mutation34,
significantly inhibited their proliferation (Fig. 6b, c). In addition,
cell-surface HER2 levels were consistently lower in SORLA-
silenced 5637 cells than their control counterparts (Supplemen-
tary Fig. 6b), albeit these data did not reach statistical significance.
Moreover, subcutaneous grafting of transiently SORLA-silenced
5637 cells (the strong anti-proliferative effect of shSORLA in vitro
precluded sufficient propagation of stably silenced cells for in vivo
experiments) in nude mice resulted in impaired tumour growth
(mean tumour volume: control-silenced tumours, 78.7 mm3 and
SORLA-silenced tumours, 47.7 mm3; p= 0.0461) (Fig. 6d, Sup-
plementary Fig. 6c). Furthermore, SORLA-silenced 5637 tumours
showed decreased proliferation, but not significantly increased
apoptosis (Fig. 6e). Finally, in line with the breast cancer data,
SORLA silencing sensitized 5637 cells to ebastine (Fig. 6f, g).
These results demonstrate that SORLA-mediated regulation of
proliferation is not only restricted to HER2-amplified breast
cancers, but is biologically important at least in HER2-driven
urothelial cancer. It may be relevant to other neoplasms as well
considering that data mining of the TCGA database revealed a
significant positive correlation between ErbB2 and SORL1
expression in testicular germ cell tumours, cervical squamous
cell carcinoma, endocervical adenocarcinoma, renal clear cell
carcinoma, sarcoma and thymoma (Supplementary Fig. 6d).
Discussion
Here we demonstrate that SORLA, a sorting protein previously
not investigated in carcinomas, is highly expressed in many
HER2-driven cancer cell lines, and that SORLA regulates
HER2 subcellular localization by forming a complex with the
receptor and coupling it to the recycling machinery (Fig. 7). We
find that HER2 distribution between the plasma membrane and
endosomes is highly heterogeneous in cancer cells; those with
lower SORLA expression exhibit a trend of harbouring a sub-
stantial pool of intracellular HER2 at steady state. Furthermore,
silencing of SORLA induces intracellular accumulation of HER2,
and overexpressing SORLA triggers cell-surface localization of
HER2. Thus, HER2 undergoes rapid endosomal trafficking and
recycling, the kinetics of which are regulated by SORLA-HER2
association. The fact that SORLA depletion (1) dramatically
reduces proliferation of HER2-driven bladder and breast cancer
cells in vitro and in vivo, (2) alters HER2 signalling, (3) interferes
with lysosome integrity and (4) provides additive pro-apoptotic
effects in combination with a clinically well-tolerated and widely
used lysosome-accumulating drug provides new insight into the
pathophysiology and targetability of HER2-driven oncogenesis.
Previous studies have shown discrepant results regarding
HER2 trafficking. While some studies have shown that HER2 is
resistant to internalization13,16,17, others have suggested rapid
recycling of HER2 back to the plasma membrane22,23. In both
scenarios, HER2 is mainly restricted to the plasma membrane
where it can associate with signalling platforms to drive the
proliferation and tumorigenesis of cancer cells. Here we investi-
gated the localization of HER2 in six different HER2-amplified
breast cancer cell lines and found very different patterns of
localization. Our observation of HER2 overlapping with EEA1-
and VPS35-positive endosomes in some of the cell lines suggests
that at least a pool of HER2 moves back to the plasma membrane
via retromer-dependent vesicle trafficking41. The heterogeneity in
the subcellular localization of HER2 is interesting, since it might
reflect the functions of HER2 and the efficiency of therapeutic
targeting of HER2. Indeed, in our study, anti-HER2 therapy
(lapatinib, trastuzumab)-resistant JIMT-1, HCC1954 and MDA-
MB-361 cell lines displayed more intracellular HER2 compared to
the therapy-sensitive BT474, HCC1419 and SKBR3 cell lines with
predominantly plasma membrane-localized HER2. This is also in
line with two recent studies, published during the course of our
investigation, that indicate a role for caveolin-1 in supporting
HER2 internalization, and, in agreement with our findings, sug-
gest that HER2 internalization and trafficking can be very dif-
ferent between different HER2-expressing cells42,43. Accordingly,
the role of HER2 trafficking and the expression levels of specific
trafficking proteins, such as caveolin-1 and SORLA, are important
for the oncogenic activity of HER2 and most importantly for the
response to anti-HER2 therapies. It is an intriguing possibility
that the reduced viability of some HER2-dependent cancer cell
lines upon depletion of trafficking proteins such as VPS35, Rab7
and LAMP144 might be related to alterations in HER2 trafficking.
The sorting functions of SORLA have been implicated in
Alzheimer’s disease and obesity27–33. We found that the ECD of
SORLA associates either directly or indirectly with HER2, while
the intracellular domain of SORLA is required for the correct
endosomal and plasma membrane localization of this molecule in
Fig. 3 SORLA promotes HER2 recycling. a, b Confocal microscopy images (a) and quantification (b) of HER2 staining after SORLA silencing (shSORLA #1
and shSORLA #4) in BT474 cells (n= 31 shCTRL, 25 shSORLA #1 and 20 shSORLA #4 cells from two experiments; analysis performed on 8-bit images;
statistical analysis: Mann−Whitney test). c, d Confocal microscopy images (c) and quantification (d) of HER2 in vehicle- and primaquine-treated (60min)
BT474 cells (n= 34 (vehicle), 28 (0.1 mM primaquine) and 34 (0.3 mM primaquine) cells; analysis performed on 16-bit images; statistical analysis: Mann
−Whitney test). e, f Microscopy analysis (e) and quantification (f) of AlexaFluor 568-labelled trastuzumab (Tz-568) internalization in MDA-MB-361 cells
silenced with SORLA (siSORLA #3) or scramble (siCTRL) siRNA at the indicated time points (mean ± s.e.m; n= 64, 77, 86 and 64 siCTRL cells and 111, 83,
103 and 87 siSORLA #3 cells at the 0, 15, 30 and 60min time points, respectively, from two independent experiments; statistical analysis: Mann−Whitney
test; a.u. arbitrary units). g Microscopy-based HER2 recycling assay in control or SORLA siRNA-treated MDA-MB-361 cells. Labelled HER2 recycling back
to the plasma membrane was monitored over 30min after an internalization step (45min) and imaged with a confocal microscope. Ratio of surface/
internalized Tz-568 signal is displayed as box plots (n= 34 and 57 siCTRL cells and 45 and 47 siSORLA cells for 0 and 45min time points, respectively,
from two independent experiments; statistical analysis: Nonparametric Kruskal−Wallis). h Immunoblotting analysis of biotin-labelled cell-surface HER2
internalization in JIMT-1 cells overexpressing SORLA-GFP (or control GFP; GFP-CTRL), and quantification of internalized HER2 relative to total HER2 (data
are mean ± s.d.; n= 4 independent experiments; statistical analysis: unpaired Student’s t test). i Quantification of HER2 recycling rate (% return of
internalized biotinylated cell-surface HER2 back to the plasma membrane after 10min) in JIMT-1 cells transfected with GFP-CTRL or SORLA-GFP following
30min of endocytosis (data are mean ± s.d.; n= 3 independent experiments; statistical analysis: unpaired Student’s t test). Scale bars: 10 µm. Box plots
represent median and IQR and whiskers extend to maximum and minimum values. Where micrographs are shown, these are representative of n= 3
independent experiments; ROI magnified region of interest
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cancer cells. Importantly, re-expression of neither ECD-TM or
TM-CD SORLA truncation mutants was sufficient to support
proliferation of SORLA-silenced cells. This suggests that both the
association of SORLA-ECD with HER2 and the correct sub-
cellular localization of the SORLA-HER2 complex are necessary
for proper SORLA function in supporting HER2-driven onco-
genesis. Whether the observed coupling between SORLA-ECD
and HER2 is mediated by direct binding or through other pro-
teins remains to be investigated.
Lysosomal function is strongly linked to cellular fitness and it is
especially important for the nutrient balance in rapidly growing
cancer cells. One important finding of our work is that SORLA
plays a major and unanticipated role in the maintenance of
lysosome function in HER2-dependent cancer cells, but not in the
FGFR2-amplified, SORLA-positive MFM-223 cancer cells. The
effects of SORLA depletion on lysosome function were two-fold.
Lysosomes in SORLA-silenced cells showed perinuclear cluster-
ing. In addition, we found that lysosomes were enlarged, dis-
played an abnormal maturation defect-like appearance and had
reduced proteolytic activity in SORLA-depleted cells. Strikingly,
after SORLA silencing, HER2 accumulated into lysosomes with-
out always being efficiently degraded (Fig. 7). The observed
modest reduction in total HER2 protein levels was consistent, but
varied in extent between experiments, which could be due to the
parallel lysosomal defect. This is in stark contrast to the rapid
lysosomal degradation of HER2 following treatment with gelda-
namycin, which inhibits HSP90-CDC37-complex-mediated sta-
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that SORLA regulates HER2 in a fundamentally distinct way than
HSP90. Possibly due to mistargeted localization and the lack of
suitable signalling co-factors on late endosomes, HER2 signalling
to the PI3K/AKT/mTOR proliferative pathway was decreased in
SORLA-silenced breast cancer cells. Interestingly, double silen-
cing of SORLA and HER2 led to a less enlarged and clustered
lysosomal phenotype suggesting that lysosomes might be over-
whelmed in the presence of excess intracellular HER2. Whether
the SORLA silencing alone induces a mild lysosomal defect
leading to HER2 accumulation in lysosomes and mislocalised
HER2 further enhances lysosomal stress remains to be elucidated.
The possible role of SORLA-dependent alterations in lipid and
glucose metabolism30–33 with respect to lysosomal dysfunction
also remains to be investigated. SORLA could additionally con-
tribute to the oncogenic properties of cancer cells by regulating
the trafficking of other cargo. For example, we find that cell-
surface β1-integrin levels are reduced and integrin recycling is
attenuated upon SORLA silencing.
We found that SORLA-silenced cells undergo apoptosis when
exposed to low doses of the antihistamine ebastine, which belongs
to a heterogeneous group of CADs with similar chemical fea-
tures47 and with a tendency to accumulate strongly in leaky
lysosomes that are common in transformed cells36,37. CADs,
including ebastine, have been utilized in several in vitro, pre-
clinical and clinical trials to target the vulnerability of lysosomes
in cancer37. Importantly, we found that both anti-HER2
Fig. 4 Silencing SORLA induces HER2 accumulation in dysfunctional lysosomes. a Immunofluorescence imaging of LAMP1 (white) and HER2 (red) in
shCTRL and shSORLA MDA-MB-361 cells (n= 3 independent experiments). b Immunofluorescence imaging of LAMP1 (green) and CD63 (LAMP3; green)
in MDA-MB-361 cells (blue is DAPI) after scramble (siCTRL) or SORLA (siSORLA #3 and siSORLA #4) siRNA silencing (n= 3 independent experiments).
c Quantification of late endosomes/lysosome aggregation after SORLA silencing in MDA-MB-361 cells. LAMP1-positive structures≥ 5 µm2 were
considered as lysosome aggregates (n= 73 siCTRL, 79 siSORLA #3 and 67 siSORLA #4 cells from three independent experiments; statistical analysis:
Mann−Whitney test). d Immunofluorescence imaging and quantification of lysosomal aggregation in MDA-MB-361 cells treated with the indicated siRNA
(n fields of view analysed, total cells= 11, 131 (siCTRL); 12, 182 (siSORLA #3); 11, 169 (siSORLA #3+ siHER2 #2); 10, 133 (siSORLA #4); 10, 121
(siSORLA#4+ siHER2 #2) from two independent experiments; statistical analysis: Mann−Whitney test). e Transmission electron microscopy imaging of
lysosomes in siCTRL or siSORLA MDA-MB-361 and BT474 cells. Red arrows indicate the maturation defect in late endosome/lysosome structures (n= 3
technical replicates). f Flow cytometry analysis of the fluorescence signal in DQ Red BSA-loaded (24 h) MDA-MB-361 cells after scramble (siCTRL) or
SORLA (siSORLA #3 and siSORLA #4) silencing. Cells loaded with DQ Red BSA (4 h) and treated with bafilomycin (or vehicle) are included as controls
(bafilomycin blocks lysosome function) (mean ± s.d.; n= 5 independent experiments; statistical analysis: unpaired Student’s t test). g Cell viability assay to
determine ebastine (48 h treatment) IC50 values in SORLA- or control-silenced BT474 and MDA-MB-361 cells (mean ± s.d.; n= 12, four technical
replicates, three independent experiments; statistical analysis: unpaired Student’s t test). h, i Immunoblotting (h) and quantification (i) of cleaved PARP1 in
ebastine-treated (15 µM, 48 h) siCTRL and siSORLA #3 or siSORLA #4 MDA-MB-361 cells. α-tubulin is a loading control (mean ± s.d.; n= 3 independent
experiments; statistical analysis: unpaired Student’s t test). Scale bars: 10 µm (a, b, d) and 1 µm (e). Box plots represent median and IQR and whiskers
extend to maximum and minimum values. Nu nucleus
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Fig. 5 SORLA has a prognostic value in HER2-amplified breast cancer. a Immunohistochemical staining of SORLA and HER2 from a breast cancer tissue
microarray (TMA; 883 patients in total). HER2-amplified tumours (199 patients) were categorized into negative/low (Neg/Lo) (staining intensity 0–1) and
moderate/high (Mod/Hi) (staining intensity 2–3) groups. Numbers indicate staining intensity, 0= negative, 1=weak, 2=moderate, 3= high. b In silico
biomarker assessment tool ((http://kmplot.com); including all datasets from 2010, 2012, 2014, 2017) analysis showing Kaplan−Meier plots of overall
survival (OS; 10 years) and relapse-free survival (RFS; 20 years) of SORLA-high and SORLA-low patients (split by the best median cutoff) within all breast
cancers (RFS n= 3955; OS n= 1402) and within HER2-amplified breast cancers (RFS n= 252; OS n= 129). Scale bars: 50 µm
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therapy-resistant and sensitive HER2-amplified breast cancer cells
are susceptible to the combination of SORLA silencing and low
doses of ebastine. Silencing SORLA alone mainly reduced pro-
liferation, but when combined with ebastine triggered enhanced
apoptosis. This additive effect could potentially be exploited by
combining current anti-HER2 therapies with CADs, since breast
cancer cells and patient-derived xenografts resistant to an anti-
HER2 drug-antibody conjugate were recently shown to possess
dysfunctional lysosomes48.
In conclusion, we have discovered that SORLA regulates the
subcellular localization of HER2 and that dynamic recycling is
essential for the oncogenic fitness of HER2. The endosomal
trafficking of HER2 could provide new rationale for designing
targeted therapies and understanding the resistance mechanisms
induced by the current HER2-targeting therapies.
Methods
Subcutaneous and ductal carcinoma in situ (DCIS) xenograft models. For
subcutaneous (s.c.) tumours, 2 × 106 siCTRL- and siSORLA #3-treated 5637
bladder cancer cells were injected s.c. (100 µl volume; 50% Matrigel, 50% PBS) at
the flank of 6-week-old nude mice. Mice were sacrificed 29 days later, and tumours
were dissected, fixed in 10% formalin, and processed for paraffin sections with
standard protocols. Sections were stained with haematoxylin-eosin (HE) and with
immunohistochemistry (IHC) antibodies against proliferation (Ki67) and apoptosis
(TUNEL) markers. Sections were imaged with a pannoramic slide scanner.
For intraductal tumour xenografts, MDA-MB-361 shCTRL and shSORLA-
silenced breast cancer cells were resuspended in PBS (2.5 × 104 cells/µl). Trypan
blue (0.1%) was added to the cell solution to visualize successful injection. Eight- to
ten-week-old female NOD.SCID mice were medicated with Temgesic for analgesia
and anesthetized with isoflurane. After removal of abdominal hair, the tip of the
abdominal (fourth) mammary glands was carefully snipped, and 4 µl (1 × 105 cells)
of cell suspension was injected into the mammary ducts. A 30 G Hamilton syringe
with 50-μl capacity and a blunt-ended needle was used for the injection under a
stereomicroscope. Post-operatively, the mice were further dosed with Rimadyl for
HER2-positive bladder cancers (n = 73/199, 36.7%)
HER2 SORLA
Chi-square test, p = 0.0092
HER2 SORLA
a
Neg/Lo SORLA Mod/Hi SORLA
HER2 (0) HER2 (1) HER2 (2 + 3)
SORLA (0) 33 (72%) 11 (24%) 2 (4%)
SORLA (1) 26 (54%) 16 (33%) 6 (13%)
SORLA (2) 26 (43%) 19 (31%) 16 (26%)
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Fig. 6 SORLA expression correlates with HER2 and promotes tumorigenesis in bladder carcinoma. a Immunohistochemical staining of a bladder cancer
TMA and correlation analyses of SORLA and HER2 levels. Numbers indicate staining intensity, 0= negative, 1=weak, 2=moderate, 3= high. b Western
blot analysis of SORLA levels in siCTRL and siSORLA (siSORLA#3, siSORLA#4) 5637 bladder cancer cells. GAPDH is a loading control. c Analysis of
siCTRL and siSORLA (siSORLA#3, siSORLA#4) 5637 cell proliferation (mean ± s.d; n= 4 independent experiments; statistical analysis: two-way ANOVA).
d Analysis of tumour growth of subcutaneously injected 5637 cells, with transient SORLA (siSORLA #3) or scramble (siCTRL) silencing, at day 29 in nude
mice (n= 9 siCTRL and 10 siSORLA mice; statistical analysis: unpaired Student’s t test). e Ki-67 and TUNEL staining of tumour samples prepared as
described in d and quantifications displayed as box plots (n= 9 siCTRL and 10 siSORLA mice; statistical analysis: Mann−Whitney test). f Colony formation
assay with SORLA-silenced and control-silenced 5637 cells treated with different concentrations of ebastine for 7 days. Quantification of confluency
was performed using ImageJ Colony Area Plug-in49. Results are shown as mean ± s.d. (n= 4 independent experiments; statistical analysis: unpaired
Students t test). Scale bars: 200 µm (a), 500 µm (e). Box plots represent median and IQR and whiskers extend to maximum and minimum values
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pain relief. Mice were sacrificed 10 weeks after tumour inoculation, and abdominal
mammary glands were dissected. Mammary gland whole mounts were prepared on
object glasses and fixed in Carnoy’s medium (60% EtOH, 30% chloroform, 10%
glacial acetic acid) overnight (o/n) at +4 °C. After rehydration in decreasing EtOH
series and staining with carmine alum (0.2% carmine, 0.5% aluminium potassium
sulphate dodecahydrate) o/n at room temperature (RT), samples were dehydrated
and cleared in xylene for 2–3 days. Samples were mounted in DPX Mountant for
histology (Sigma) and images were taken with Zeiss SteREO Lumar
V12 stereomicroscope (NeoLumar ×0.8 objective, Zeiss AxioCam ICc3 colour
camera). All images per gland were combined automatically into a mosaic picture
with PhotoShop. DCIS area per gland was quantified in ImageJ.
All animal studies were ethically performed and authorized by the National
Animal Experiment Board and in accordance with The Finnish Act on Animal
Experimentation (Animal license number ESAVI-9339-04.10.07-2016).
Cell lines and cell culture. MDA-MB-361 cells (ATCC, HTB-27) were grown in
Dulbecco’s modified essential medium (DMEM; Sigma-Aldrich, D5769) supple-
mented with 20% foetal bovine serum (FBS; Sigma-Aldrich, F7524), 1% vol/vol
penicillin/streptomycin (Sigma-Aldrich, P0781-100ML) and L-glutamine. BT474
(ATCC, HTB-20) and 5637 (ATCC, HTB-9) cells were grown in RPMI-1640
(Sigma-Aldrich, R5886) supplemented with 10% FBS, 1% vol/vol penicillin/strep-
tomycin and L-glutamine. JIMT-1 (DSMZ, ACC 589), HCC1954 (ATCC, CRL-
2338), HCC1419 (ATCC, CRL-2326), MCF7 (ATCC, HTB-22), MDA-MB-231
(ATCC, HTB-26), MDA-MB-436 (ATCC, HTB-130) and MFM-223 (DSMZ,
ACC-422) were grown in DMEM supplemented with 10% FBS, 1% penicillin/
streptomycin and L-glutamine. MCF10A (ATCC, CRL-10317) and MCF10A DCIS.
com (provided by Prof. J.F. Marshall, Barts Cancer Institute, Queen Mary Uni-
versity of London, London, UK) were grown in DMEM/F12 (Invitrogen, #11330-
032) supplemented with 5% horse serum (Invitrogen#16050-122), 20 ng/ml human
epidermal growth factor (Sigma-Aldrich, E9644), 0.5 mg/ml hydrocortisone
(H0888–1G; Sigma-Aldrich), 100 ng/ml insulin (Sigma-Aldrich, I9278-5ML) and
1% vol/vol penicillin/streptomycin. All cells were regularly tested for mycoplasma
infection and were grown at +37 °C, 5% CO2 until 70–80% confluence before being
detached and replated. The medium was changed every 3 days. T24 (ATCC, HTB-
4) and SKBR3 (ATCC, HTB-30) cells were grown in McCoy’s 5a Medium Modified
(Sigma-Aldrich, M8403-500ML) supplemented with 10% FBS, 1% penicillin/
streptomycin and L-glutamine, and the patient-derived bladder carcinoma line
(provided by Dr. P. Taimen, Turku University Hospital, Turku, Finland) was
grown in F-medium (3:1 (v/v) F-12 Nutrient Mixture (Ham): DMEM (Invitrogen)
supplemented with 5% FCS, 0.25 µg/ml hydrocortisone, 5 mg/ml insulin, 10 mg/ml
gentamicin, 250 µg/ml fungizone, 8.6 ng/ml cholera toxin, 125 ng/ml EGF) col-
lected from irradiated Swiss 3T3 J2 mouse fibroblast feeder cell cultures and
supplemented with 10 µM ROCK inhibitor (Y-27632, Enzo Life Sciences, Lausen,
Switzerland).
Antibodies. The antibodies used are described in Supplementary Table 1.
Generation of lentiviral shRNA and SORLA-GFP particles. Lentiviral particles
containing sequences encoding shRNA against SORLA and GFP or a control
scramble shRNA sequence and GFP or particles encoding for SORLA-GFP or GFP
alone were generated in the 293FT packaging cell line (complete medium: high
glucose DMEM, 10% FBS, 0.1 mM NEAA, 1 mM MEM Sodium Pyruvate, 6 mM L-
glutamine, 1% penicillin/streptomycin and 0.5 mg/ml Geneticin) by transient
transfection of transfer vector (#TL309181A SORL1 SR031650, #TL309181B
SORL1 SR031650, #TL309181C SORL1 SR031650, #TL309181D SORL1 SR031650,
or scramble control (#TR30021, Origene), second-generation packaging plasmid-
psPAX2 (Addgene #12259) and envelope vector-pMD2 (Addgene #12260) with the
ratio (7:2:1) using calcium-phosphate precipitation method50. Seventy-two hours
post transfection, medium containing viral vectors was collected, concentrated for
2 h by ultracentrifugation (26,000 × g) in a swing-out rotor SW-32Ti (Beckman
Coulter, Brea, CA, USA), resuspended in residual medium and flash frozen in
liquid nitrogen. Functional titre was evaluated in 293FT cells by FACS (BD
LSRFortessa, Becton Dickinson).
Lentiviral transduction to generate stable cell lines. To generate stable silenced
cell lines 4 × 105 BT474 or MDA-MB-361 cells were seeded on 10 cm dishes and
transduced 24 h later with MOI 47 of lentivirus in a low volume of full media. To
obtain stable overexpression of SORLA-GFP or GFP, 8 × 104 JIMT-1 or MDA-MB-
361 cells were seeded in a 24-well plate and transduced 24 h later with MOI 60.
Medium containing viral particles was removed 16 h later. Cells expressing GFP,
indicative of lentiviral integration were collected by fluorescence-assisted cell
sorting (BD FACSaria II cell sorter, Becton Dickinson, Franklin Lakes, NJ, USA)
with a gating strategy to obtain medium expression.
Transient transfections. For transient protein expression, Lipofectamine 3000
(Invitrogen, P/N 100022052) and P3000 enhancer reagent (Invitrogen, P/
N100022058) were used according to the manufacturer’s instructions. Cells were
transfected with plasmids 24 h prior to experiments. Transient siRNA transfections
were performed using Lipofectamine RNAiMAX reagent (Invitrogen, P/N 56532)
according to the manufacturer’s instructions. SORLA-targeting siRNAs were ON-
TARGETplus obtained from Dharmacon—siSORLA #1 (J-004722-08), siSORLA
#2 (J-004722-06), siSORLA #3 (J-004722-07), siSORLA #4 (J-004722-05). For
rescue experiments, siRNA against the 3′UTR end of SORLA was obtained from
Qiagen (siSORLA 3′UTR, SI05039888). HER2-targeting siRNAs were ON-
TARGETplus obtained from Dharmacon (siHER2 #2, J-003126-17; siHER2 #4, J-
003126-20). For controls, Allstars negative control (Qiagen, Cat. No. 1027281) was
used. SiRNA concentrations used ranged between 20 and 40 nM and cells were
transfected with siRNAs 48 h prior to experiments.
The corresponding oligonucleotide sequences can be found in Supplementary
Table 2.
Western blot analysis. Protein extracts were separated using SDS-PAGE under
denaturing conditions (4–20% Mini-PROTEAN TGX Gels) and were transferred to
nitrocellulose membranes (Bio-Rad Laboratories). Membranes were blocked with
Sensitivity to CADs














Fig. 7 Schematic illustrating the role of SORLA in the oncogenic fitness of HER2 in cancer cells. SORLA, through interactions at its extracellular domain, is in
a complex with HER2 and co-traffics with HER2, facilitating HER2 recycling to the plasma membrane to support HER2 downstream signalling. In the
absence of SORLA, HER2 becomes localized to enlarged, partially dysfunctional lysosomes resulting in defective HER2 signalling and increased sensitivity
to cationic amphiphilic drugs (CADs) like ebastine. End endosome, Lys lysosome
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5% milk-TBST (Tris-buffered saline and 0.1% Tween 20) and incubated with the
indicated primary antibodies overnight at +4 °C. Primary antibodies were diluted
in blocking buffer (Thermo, StartingBlock (PBS) blocking, #37538) and PBS (1:1
ratio) mix and incubated overnight at +4oC. Primary antibody dilutions used
ranged from 1:500 to 1:1000. After primary antibody incubation, membranes were
washed three times with TBST and incubated with fluorophore-conjugated sec-
ondary antibodies diluted (1:1000) in blocking buffer at RT for 1 h. Membranes
were scanned using an infrared imaging system (Odyssey; LI-COR Biosciences).
The following secondary antibodies were used: donkey anti-mouse IRDye 800CW
(LI-COR, 926-32212), donkey anti-mouse IRDye 680RD (LI-COR, 926-68072),
donkey anti-rabbit IRDye 800CW (LI-COR, 926-32213) and donkey anti-rabbit
IRDye 680RD (LI-COR, 926-68073). All original western blots for the manuscript
can be found in Supplementary Fig. 7.
Co-immunoprecipitations. Cells were lysed in IP-lysis buffer (0.5% Triton X-100,
10 mM Pipes, pH 6.8, 150 mM NaCl, 150 mM sucrose, 3 mM MgCl2 and complete
protease and phosphatase inhibitors (Mediq; Roche)), cleared by centrifugation
(13,226 × g, 10 min, 4 °C), and incubated with GFP-trap beads to pull-down GFP-
proteins (Chromotek; gtak-20) for 1 h at +4 °C or with mouse anti-HER2 antibody
(1 µg/sample; ThermoScientific, MA5-14057) or isotype matching IgG control
antibody at +4 °C overnight. Antibody complexes were bound to 0.5% BSA pre-
blocked protein-G sepharose beads for 1 h at 4 °C. Complexes bound to the beads
were isolated using 1000 × g 3 min centrifugation, washed three times with washing
buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 % NP-40; 500 µl) and eluted in
sample buffer. Input and precipitate samples were analysed by western blotting.
Primary antibodies were incubated overnight at +4 °C. Mouse anti-HER2 (Ther-
moScientific; MA5-14057), rabbit anti-GFP (Molecular Probes; A11122) and
mouse anti-SORLA (anti-LR11, BD Transduction Lab; 612633) diluted 1:1000 in
5% milk in TBST were used followed by the appropriate IRDye conjugated sec-
ondary antibodies.
Immunofluorescence staining and imaging. Cells were plated on µ-Slide 8-well
(Ibidi, 80826) or in some cases in µ-dish 3.5 mm dishes (Ibidi, 80136). Cells were
fixed with 4% paraformaldehyde (PFA) 10 min at RT, quenched with 50 mM
NH4Cl for 15 min at RT, blocked and permeabilized with 30% horse serum in PBS
+ 0.3% Triton X-100 for 10 min at RT and incubated with primary antibodies
diluted in 30% horse serum overnight at +4°C. Staining was performed using
antibodies against HER2 (trastuzumab, Roche, 0.15 μg/ml; or mouse monoclonal
antibody, ThermoScientific, MA5-14057, 1:300 dilution), LAMP1 (Santa Cruz; SC-
20011 (H4A3), dilution 1:50), SORLA (rabbit monoclonal, CM Petersen Lab,
Århus University, dilution 1:300), EEA-1 (goat polyclonal, Santa Cruz; sc-6415,
dilution 1:50), VPS35 (goat polyclonal, Abcam; ab10099, dilution 1:300), CD63
(mouse mAb, Hybridoma Bank; H5C6, dilution 1:300) and Rab11 (rabbit poly-
clonal, Cell Signaling Technology, #5589, dilution 1:100). After several washes,
appropriate secondary antibodies (donkey anti-mouse AlexaFluor 488 (Life
Technologies, A21202), donkey anti-rabbit AlexaFluor 488 (Invitrogen), goat anti-
human AlexaFluor 568 (Invitrogen, A21090), donkey anti-goat AlexaFluor 647
(Invitrogen, A21447), donkey anti-mouse AlexaFluor (Invitrogen, A31571)) dilu-
ted 1:300 in 30% horse serum were added together with DAPI (1:1000) for 1 h at
RT. After PBS washes, samples were imaged right away or stored at +4°C in the
dark. Imaging was performed either with a Carl Zeiss LSM780 laser scanning
confocal microscope or a 3i CSU-W1 spinning disk confocal microscope with
Hamamatsu CMOS (×63 objective).
Transmission electron microscopy. Cells were fixed in 5% glutaraldehyde in 0.16
M s-collidine buffer, pH 7.4. The samples were post-fixed for 2 h with 1% OsO4
containing 1.5% potassium ferrocyanide, dehydrated with a series of increasing
ethanol concentrations and embedded in 45359 Fluka Epoxy Embedding Medium
kit. 70-nm sections were cut with an ultramicrotome and stained with 1% uranyl
acetate and 0.3% lead citrate. The sections were examined with a JEOL JEM-1400
Plus transmission electron microscope.
Live-cell imaging. Lentiviral transduced SORLA-GFP-expressing MDA-MB-
361 cells were kept on ice and washed twice with ice-cold PBS. Alexa-568-
conjugated trastuzumab (0.15 μg/ml) in Hank’s Balanced Salt Solution was incu-
bated with the cells on ice for 1 h protected from light. The cells were washed twice
with ice-cold PBS before addition of pre-warmed culture media supplemented with
5% HEPES (without serum). Imaging was performed with Deltavision OMX V4
total internal reflection microscopy (TIRFM; GE Healthcare) every 250 ms with a
×60/1.49 objective (Olympus TIRF objective).
Proliferation assay. Cells, transfected as indicated, were plated on 96-well plates
(3000 cells/well) in a volume of 100 µl. After 1, 4 and 8 days of cell growth, 10 µl/
well of WST-8 reagent (cell counting kit 8, Sigma-Aldrich, 96992) was added and
absorbance at 450 nm was measured by a plate reader (Thermo, Multiscan Ascent)
after 1–2 h of incubation at +37 °C with 5% CO2. Medium without cells was used
as background and the A450 of background was subtracted from the samples.
Relative proliferation was calculated by normalizing the A450 values of 4 and
8 days to 1 day A450 values. For drug sensitivity assays cells were treated the
following day after plating with increasing concentrations of ebastine (BT474: 2, 4,
8, 16, 32 µM and MDA-MB-361: 2, 4, 8, 16, 32, 64 µM). DMSO was used as a
control and proliferation was measured after 48 h.
Analysis of SORLA and HER2 cell-surface levels. Cells were detached by
HyQtase, fixed with 4% PFA (in PBS for 15 min at RT), and washed before
labelling with 1:1000 dilution of a mouse anti-HER2 antibody (9G6, Abcam;
Ab16899), or 1:100 dilution of a goat anti-SORLA primary antibody28. After
washing with PBS, samples were incubated with donkey anti-mouse AlexaFluor
647, donkey anti-mouse AlexaFluor 488 or donkey anti-goat AlexaFluor 488 sec-
ondary antibody (dilution 1:300 in PBS; all from Invitrogen), washed with PBS and
analysed with LSRFortessa (BD Biosciences). Data analysis was performed with
Flowing software version 2 (Cell Imaging Core of the Turku Bioscience Centre).
The geometric mean of the fluorescence intensity from cells labelled with sec-
ondary antibody alone was used as background and subtracted from the stained
samples. For normalization, the background corrected values were divided by the
sum of all signals within one independent experiment.
Representative raw flow cytometry data can be found in Supplementary Fig. 8.
DQ Red BSA assay. For microscopy assays, silenced cells were plated on ibidi 8-
well µ-slide 72 h post transfection. On the next day, the medium was replaced with
DQ Red BSA (ThermoScientific, D12051)-containing medium (25 µg/ml, 200 µl/
well) and cells were incubated for 48 h at 37 °C with 5% CO2, the cells were washed,
fixed with 4% PFA for 10 min at RT, washed again and imaged with a Carl Zeiss
LSM780 laser scanning confocal microscope.
For flow cytometry assays, the cells were silenced and loaded with DQ Red BSA
(25 µg/ml, 1 ml per well in six-well plates for 24 h) as above. When indicated, 25
nm bafilomycin (Calbiochem, 196000-10UG) or DMSO only was added to DQ Red
BSA and the loading was shortened to 4 h. The loaded cells were detached with
HyQtase, washed, fixed with 4% PFA for 15 min at RT, washed, and analysed using
LSRFortessa (BD Biosciences) and Flowing software. Fluorescence signals from
unstained cells (background) were subtracted from the DQ Red BSA signals and
geometric means were plotted.
Representative raw flow cytometry data can be found in Supplementary Fig. 8.
RNA extraction, cDNA synthesis and qPCR. Cells were lysed in RA lysis buffer
and RNA was extracted according to the manufacturer’s instructions (NucleoSpin
RNA extraction kit, Macherey−Nagel, 740,955.5). RNA concentration was mea-
sured by NanoDrop Lite (Thermo). Complementary DNA (cDNA) was synthe-
sized using a high-capacity cDNA Reverse Transcription Kit (Applied Biosystems)
according to the manufacturer’s instructions. Quantitative real-time PCR reactions
with TaqMan probes were performed according to the manufacturer’s instructions
(Thermo/Applied Biosystems, TaqMan™ Universal Master Mix II, 4440040). The
following TaqMan probes (ThermoScientific, 4331182) were used: ErbB2
(Hs01001580_m1). Relative quantification of gene expression values were calcu-
lated using the ddCt method51.
Biotin-based HER2 endocytosis assay. HER2 endocytosis was measured using a
cell-surface biotinylation-based assay as previously described52. Briefly, JIMT-1
cells expressing GFP-CTRL or SORLA-GFP were grown to 80% confluence, placed
on ice, and washed once with cold PBS. Cell-surface proteins were labelled with
0.5 mg/ml of EZ-link cleavable sulfo-NHS-SS-biotin (#21331; Thermo Scientific) in
Hanks’ balanced salt solution (H9269; Sigma) for 30 min at 4 °C. Unbound biotin
was removed by washing with cold Hanks’ balanced salt solution. Thereafter, the
cells were allowed to internalize receptors in pre-warmed 10% serum-containing
medium at +37 °C for the indicated times. Internalization was stopped by trans-
ferring the cells to ice and adding cold medium. The remaining biotin on the cell
surface was removed with 60 mM MesNa (63705; sodium 2-mercaptoethane-
sulfonate: Fluka) in MesNa buffer (50 mM Tris-HCl [pH 8.6], 100 mM NaCl) for
30 min at 4 °C, followed by quenching with 100 mM iodoacetamide (IAA, Sigma)
for 15 min on ice. To detect the total surface biotinylation, plates were left on ice
after the biotin labelling and MesNa treatment was omitted. Cells were then
washed with PBS, scraped in lysis buffer (50 mM Tris pH 7.5, 1.5 % Triton X-100,
100 mM NaCl, complete protease and phosphatase inhibitors (Mediq; Roche)) at
4 °C for 20 min. After clarification by centrifugation (14,000 × g, 10 min, 4 °C),
HER2 was immunoprecipitated from the supernatants with appropriate antibodies
and protein G sepharose beads (17-0618-01; GE Healthcare). The immunopreci-
pitates were eluted in non-reducing Laemmli sample buffer and subjected to
western blotting as described above. Biotinylated (internalized) HER2 and total
receptor levels were detected by immunoblotting with horseradish peroxidase
(HRP)-conjugated anti-biotin antibody (#7075; Cell Signaling Technology) and
receptor-specific antibodies, respectively. Enhanced chemiluminescence-detected
biotin and receptor signals were quantified as integrated densities of protein bands
with ImageJ (v. 1.43 u), and each biotin signal was normalized to the corresponding
receptor and total biotin signals.
HER2 recycling assay in JIMT-1 SORLA-GFP cells. HER2 recycling was mea-
sured using a cell-surface biotinylation-based assay as previously described52. Cell-
surface proteins were biotinylated and allowed to be internalized as described
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above for 30 min. After the first MesNa/IAA treatment, the internalized biotiny-
lated fraction of receptors was then chased for the indicated time points by
returning cells to 37 °C with pre-warmed medium containing 10% FBS, followed by
a second MesNa/IAA treatment to cleave biotin from the recycled cell-surface
proteins. HER2 was immunoprecipitated and analysed for biotinylation and total
levels as in the endocytosis assay.
Alternatively, biotinylated HER2 was determined by capture ELISA as described
previously53 using trastuzumab (Herceptin) or c-erbB-2 (A0485, Dako). Briefly, 50
µl of the antibody (5 µg/ml diluted in 0.05M Na2CO3 pH 9.6) was added into 96-
well plates (Maxisorb, Thermo Scientific Nunc-Immunoplate) and incubated o/n at
+4 °C. Plates were washed with 0.1% PBS-T and blocked with 5% BSA (41-00-410,
First Link) in 0.1% PBS-T for 2 h at RT. The plate was washed extensively with
0.1% PBS-T and the biotinylated lysate was added and incubated o/n at +4 °C. On
the following day the plate was washed extensively with 0.1% PBS-T and the
secondary antibody (Pierce High Sensitivity Streptavidin-HRP 21130) was added in
1:1000 in 1% BSA in 0.1% PBS-T and incubated for 2 h at RT. The plate was then
washed extensively with 0.1% PBS-T and once with PBS and 50 µl of the detection
reagent (0.8 mg/ml of O-Phenylenediaminedihydrochloride (Sigma) in detection
buffer (25.4 mM Na2HPO4, 12.3 mM citric acid, pH 5.4) supplemented with 0.2 µl/
ml of H2O2 was added. Incubation was continued until colour formation (2–15
min) and stopped by addition of 50 µl of 8 M H2SO4 and absorbance was read at
490 nm.
Imaging-based HER2 internalization and recycling assay. MDA-MB-361 cells
were plated on ibidi 35 mm µ-dishes after 72 h of silencing. The following day, cells
were washed once with PBS and incubated with Alexa-568-conjugated trastuzumab
(Tz-568; 0.15 µg/ml) in cold Hank’s Balanced Salt Solution on ice for 1 h protected
from light. Internalization was triggered with a temperature shift by adding pre-
warmed serum-free media to the cells and incubating at +37 °C for the indicated
times. The 0 min sample serves as the no internalization control. The antibody
internalization was stopped by washing with cold PBS and fixing with 4% PFA for
10 min at RT. Fixed cells were washed and stored at +4 °C in the dark until
imaging with 3i spinning disk confocal microscope. The recycling experiments
were performed in DMEM+ 10% FBS, and the antibody internalization (Tz-568; 2
µg/ml) was allowed to proceed for 45 min at +37 °C. This was followed by an acid
wash (0.2 M acetic acid, 0.5 M NaCl, pH 2.5) to remove surface-bound antibodies.
After three washes with PBS, the cells were overlaid with DMEM+ 10% FBS and
incubated for 0 or 30 min at +37 °C to allow antibody recycling and followed by
fixation with 4% PFA. Imaging was performed with Leica SP5 confocal microscope.
Immunohistochemistry, Ki-67 and TUNEL labelling. Formalin-fixed, paraffin-
embedded tissue samples were cut to 4 µm sections, and deparaffinized and
rehydrated with standard procedures. For immunohistochemistry of mouse
xenografts, heat-mediated antigen retrieval was done for all samples in citrate
buffer (pH 6). For Ki-67 labelling, sections were washed with washing buffer (Tris-
HCl 0.05M pH 7.6, 0.05 % Tween 20) and Normal Antibody Diluent (NABD;
Immunologic, BD09-125) and incubated with a Ki-67 antibody (14-5698,
eBioscience, clone SolA15, diluted 1:2000) for 1 h. After washes, samples were
incubated in 3% H2O2 Tris-HCl for 10 min and washed again. Samples were
incubated for 30 min with Rat probe (Biocare Medical rat on mouse HRP-polymer
RT517 –kit), washed, and further incubated with R-O-M HRP-polymer (Biocare
Medical rat on mouse HRP-polymer RT517 –kit) for 30 min. After washes, DAB
solution (DAKO K3468) was added for 10 s followed by washing. After counter-
stain with Mayer’s HTX, slides were dehydrated, cleared in xylene and mounted.
For TUNEL staining of apoptotic cells, endogenous peroxidase activity was
blocked with incubation in 3% H2O2 in PBS for 15 min. The reaction mix
containing recombinant terminal transferase (Cat. No. 03 333 566 001, Roche),
CoCl2 and Biotin-16-dUTP (11 093 070 910, Roche) in TdT buffer (1 M potassium
cacodylate, 3% BSA in PBS, pH 6.6) was applied on slides and incubated for 1 h at
+37 °C in a humidified chamber. As a positive control, one section was incubated
for 30 min in DNAse solution at +37 °C before TUNEL staining, and as a negative
control, the reaction mix was added without the transferase. Then the samples were
incubated with End reaction solution (300 mM NaCl, 30 mM sodium citrate) for
30 min at RT and washed. Blocking was done with 3% BSA in PBS 45 min at RT
after which the samples were incubated with ExtrAvidine (1:500 dilution in 1%
BSA/PBS) for 30 min at +37 °C in a humidified chamber. After PBS washes, DAB
solution (DAKO K3468) was added for 10 s followed by washing. After
counterstain with Mayer’s HTX, the slides were dehydrated, cleared in xylene,
mounted and imaged with a Pannoramic 250 Slide Scanner (3DHISTECH Ltd).
For bladder cancer TMA immunohistochemistry, BenchMark XT automated
IHC/ISH slide staining system (Ventana Medical Systems, Inc.) with Cell
Conditioning Solution (CC1) as a pretreatment was used for anti-HER2/neu
(rabbit monoclonal, Ventana clone 4B5, 24 min incubation) and anti-EGFR (rabbit
monoclonal, Ventana clone 5B7, 32 min), followed by UltraView Universal DAB
Detection Kit (Ventana). For SORLA staining, antigen retrieval pre-treatment was
first done by microwaving the slides in citrate buffer (pH 6). Lab Vision autostainer
(Thermo Fisher Scientific) with SORLA antibody (rabbit polyclonal, Atlas
Antibodies HPA 031321; 1:300 dilution) was used and primary antibodies were
detected with PowerVision Poly-HRP anti-mouse/anti-rabbit IHC system (Leica
BioSystems). Finally, the slides were counterstained with haematoxylin.
IHC staining intensities of each tissue core were visually scored for SORLA as 0
(negative), 1 (weak to moderate), or 2 (strong), and for HER2 and EGFR as 0
(negative), 1 (weak), 2 (moderate) or 3 (strong). SORLA and HER2/EGFR staining
was evaluated independently by two readers and the mean and maximum values of
three tissue cores were determined for each patient. In the final statistical analysis,
maximum scores for all the staining were used.
For the FinHer Breast Cancer tissue microarray immunohistochemistry,
deparaffinized tissues were incubated in hydrogen peroxidase to block endogenous
peroxidase activity, and antigen was unmasked by using sodium citrate (10 mmol/
L, pH 6.0) and 2100 Antigen Retriever instrument (Aptum Biologics Ltd.,
Southampton, UK). SORLA antibody (rabbit polyclonal, Atlas Antibodies HPA
031321; 1:200 dilution) was diluted in a Normal antibody Diluent (Immunologic,
Duiven, The Netherlands), and incubated on slides for 1 h at RT. Binding of the
primary antibody was detected and visualized by using the BrightVision Poly-HRP
anti-Rabbit kit (Immunologic) and 3,3′-diaminobenzidine (ImmPACT™ DAB,
Vector Laboratories, Burlingame, CA, USA) following the manufacturer’s
recommendations. The slides were counterstained with Mayer’s haematoxylin.
Tissue microarray construction. Bladder cancer TMA construction was approved
by the Research Ethics Board of the Hospital District of Southwest Finland
(1.8.2006/301). FFPE tissue samples from consecutive 199 patients who underwent
radical cystectomy in Turku University Hospital between 1985 and 2005 were used
and three 1 mm tissue cores per patient were punched for TMA. Average age at
cystectomy was 64 and none received neoadjuvant therapies. FinHer series TMA
has been described previously1.
Quantification of intracellular HER2 levels. Several fields were randomly imaged
with identical microscope settings. ImageJ was used for analysis and quantifica-
tions. Intracellular Tz-568 fluorescence signal was analysed from maximal intensity
projections of six planes taken from the middle of the cell (determined by DAPI
signal). Intracellular endogenous HER2 fluorescence intensity was measured from a
single middle plane of the cell. Intracellular signal was quantified by manually
gating the intracellular part of the cell and the intracellular signal was measured
and normalized to the cell area. Results are pooled from two independent biological
replicates.
Quantification of late-endosome/lysosome aggregation. SORLA-silenced and
control-silenced cells were fixed and stained for LAMP1 (Santa-Cruz, SC-20011)
and DAPI as described above. Cells were imaged with identical microscope settings
with a Carl Zeiss LSM780 laser scanning confocal microscope. Image processing
and quantifications were performed with the ImageJ software. The level of LAMP1-
positive late-endosome/lysosome aggregation was quantified from the middle
plane. To distinguish between individual late-endosome/lysosome aggregates,
watershed segmentation was used before quantification. The areas of late-endo-
some/lysosome aggregates were quantified from a single cell. A LAMP1-positive
area larger than 5 µm2 was considered as aggregate. Total area of LAMP1-positive
late endosomes/lysosomes was calculated based on LAMP1 staining as well as the
area of aggregates larger than 5 µm2. The percentage of lysosomal aggregation was
determined by the ratio of area of aggregates larger than 5 µm2 to total LAMP1-
positive late-endosome/lysosome area.
Analysis of Ki-67 and TUNEL staining in 5637 cell xenografts. Pannoramic
viewer (3DHISTECH Ltd) was used to scan histology slides and export images (×2
magnification) for image processing and quantifications, which were performed
identically for all the samples with the ImageJ software. The TUNEL- and Ki-67-
positive tumour areas were thresholded with MaxEntropy and quantified. The ratio
of Ki-67-positive (or TUNEL-positive) area to total tumour area was calculated.
Co-localization analysis. Pixel-intensity-based Pearson correlation coefficient (R)
between two channels was calculated using coloc2 plugin (https://imagej.net/
Coloc_2) of ImageJ v1.51s with default parameters. Percentage co-localization
between the vesicular particles was done using ComDet 0.3.6.1 (https://github.com/
ekatrukha/ComDet) plugin of ImageJ v1.51s. Particles were detected in both
channels independently at approximated particle sizes of four pixels with sensi-
tivities of signal/noise ratio of 4. Co-localization was determined based on a
maximum distance between two particle centres of five pixels and expressed as a
percentage.
Colony formation assay. Cells, silenced as indicated for 48 h, were plated on six-
well plates (1 × 104 cells/well) and exposed the following day to different con-
centrations of the indicated drugs and control cells were treated with DMSO. Drug-
containing medium was replenished after 3–4 days and the cells were fixed and
stained with 0.2% crystal violet in 10% EtOH for 10 min at RT after 7 days of
treatment. Dried plates were then scanned, and the confluency of cells per well was
quantified by using the ImageJ (NIH) ColonyArea plug-in49.
Statistical analysis. The GraphPad Prism software and two-tailed Student’s t test
(paired or unpaired, as appropriate) was used for statistical analysis. Normal
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10275-0
14 NATURE COMMUNICATIONS |         (2019) 10:2340 | https://doi.org/10.1038/s41467-019-10275-0 | www.nature.com/naturecommunications
distribution of the data was tested with the Shapiro−Wilk normality test. Unpaired
t test was used when normality could not be tested (n < 8). When data were not
normally distributed, a Mann−Whitney test was used. In proliferation assays, two-
way ANOVA was used. P values < 0.1 are shown in graphs.
Data availability
Breast cancer patient survival data are available from the Kaplan−Meier Plotter in silico
biomarker assessment tool (http://kmplot.com) including all RNA expression datasets
from 2010, 2012, 2014, and 2017. All the remaining data supporting the findings of this
study are available within the paper and its supplementary information files, or from the
corresponding author on reasonable request.
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